Results 191 to 200 of about 61,167 (243)

TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response. [PDF]

open access: yesHum Vaccin Immunother
Yang JX   +13 more
europepmc   +1 more source

Discovery and structural investigation of Varicella-Zoster virus gE-neutralizing antibodies isolated from a convalescent patient. [PDF]

open access: yesProtein Cell
Wang L   +13 more
europepmc   +1 more source

Identification of linear B-cell epitopes on the gE envelope protein of varicella-zoster virus. [PDF]

open access: yesMicrobiol Spectr
Niu Y   +8 more
europepmc   +1 more source

Varicella Zoster Virus

Collegian, 1999
Because of its ability to produce two clinically distinct disease entities (chickenpox and shingles), varicella zoster virus (VZV) is an unusual etiologic agent. Although in the past viral exanthems were mostly only of academic interest to the practitioner, the development of antiviral agents and the newly approved varicella (OKA) vaccine have ...
M L, McCrary, J, Severson, S K, Tyring
openaire   +4 more sources

Incubation of Varicella-Zoster Virus

Archives of Pediatrics & Adolescent Medicine, 1984
To the Editor.—The report by Gustafson et al1reemphasized the perplexing problems that varicella-zoster virus (VZV) create for infection containment within hospitals, particularly the risk posed by medical care providers with community-acquired varicella.
M G, Myers, W J, Hierholzer
openaire   +2 more sources

Home - About - Disclaimer - Privacy